Dr. Falk Pharma Acquires Kynos Therapeutics, Enhancing Portfolio in Inflammatory Diseases

Dr. Falk Pharma GmbH, based in Freiburg, Germany, has announced its acquisition of Kynos Therapeutics Ltd. The latter is a biopharmaceutical firm from Scotland focused on novel treatments for inflammatory diseases. This integration adds Kynos's lead asset, KNS366, a selective inhibitor targeting the enzyme kynurenine 3-monooxygenase, to Dr. Falk Pharma's portfolio. KNS366 has demonstrated safety and tolerance in Phase I trials, showing potential in treating acute pancreatitis, a focus for future research.

Acute pancreatitis remains a critical medical challenge, affecting approximately 240,000 people in Europe and 300,000 in the United States annually. Despite its prevalence, there are no proven treatments to prevent severe outcomes, highlighting the necessity for innovative approaches. KNS366's potential to address this gap positions it as a promising candidate in the R&D pipeline.